For a patient with active lung cancer, can physicians administer the pneumococcal vaccine and the annual influenza vaccine, and is a Medicare-covered physical examination appropriate?

Vaccination in Active Lung Cancer: Clear Recommendations

Yes, physicians should absolutely administer both pneumococcal and influenza vaccines to patients with active lung cancer, and Medicare-covered physical examinations are entirely appropriate for these patients. 1, 2

Influenza Vaccination

Annual influenza vaccination is explicitly recommended for all patients with cancer, including those with active lung cancer. 1, 2 The 2024 ASCO and NCCN guidelines are unequivocal on this point:

• Use only inactivated or recombinant influenza vaccine - never the live attenuated nasal spray vaccine 2
• Administer annually regardless of cancer treatment status 1
• Timing can be flexible: vaccination can occur at the time of chemotherapy administration (day 1) or during the cytopenic period (day 11) with similar immunogenicity 2

Safety Evidence

The concern about immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors has been thoroughly investigated. Multiple studies confirm that influenza vaccination does NOT increase irAEs in lung cancer patients on ICIs 3, 4. In a cohort of 370 patients on ICIs who received flu vaccine, IRAE rates (18-20%) were comparable to published clinical trial rates and no grade 5 events occurred 4.

Pneumococcal Vaccination

Pneumococcal vaccination is recommended for all adults aged ≥19 years with cancer 1, 2. For patients with active lung cancer, the specific schedule is:

For Vaccine-Naïve Patients:

• First choice: Single dose of PCV20 (no additional PPSV23 needed) 2
• Alternative: PCV15 followed by PPSV23 at least 8 weeks later 2

For Previously Vaccinated Patients:

• If received PPSV23 only: Give PCV20 (preferred) or PCV15 2
• If received PCV13 only: Give PCV20 at least 1 year later 2
• If received PCV13 + PPSV23: Give PCV20 at least 5 years later 2

Important Caveats:

• Immunocompromised patients may have diminished immune response but vaccination still provides meaningful protection 5
• The vaccine does not replace antibiotic prophylaxis when indicated 5
• Defer vaccination during moderate or severe acute illness 5

Optimal Timing Strategy

Ideally, vaccinate at least 2 weeks before starting immunosuppressive therapy 2. However, this is often not feasible in cancer patients. The practical approach:

• Do not give vaccines on the same day as cytotoxic chemotherapy (may reduce immune response) 2
• Vaccinate between chemotherapy cycles when possible for better response rates 2
• If vaccinated <2 weeks before or during therapy, consider revaccination ≥3 months after therapy completion 2

Medicare Physical Examinations

Medicare-covered physical examinations are entirely appropriate and should be utilized as opportunities for vaccination 6. In fact, hospitalization and routine medical visits represent critical opportunities to address vaccination gaps. Historical data shows that up to 80% of hospitalized Medicare patients missed opportunities for pneumococcal vaccination and 65% for influenza vaccination 6.

Common Pitfalls to Avoid

1. Never use live attenuated influenza vaccine (nasal spray) in immunocompromised cancer patients 2
2. Do not withhold vaccines due to fear of irAEs - evidence shows they are safe during ICI therapy 3, 4
3. Do not assume prior vaccination is adequate - verify specific vaccine history and follow current CDC schedules 2
4. Do not forget household contacts - they should also receive annual influenza vaccination to protect the patient 2

Clinical Rationale

Patients with lung cancer face substantially elevated risks from vaccine-preventable infections. Influenza infections in immunocompromised cancer patients are associated with hospitalizations, chemotherapy delays, and occasionally death 2. Pneumococcal disease causes significant morbidity in this population. The potential protection from vaccination, even if attenuated by immunosuppression, is superior to no protection 2.

Bottom line: Vaccinate your lung cancer patients. The evidence strongly supports both safety and benefit, and current guidelines from ASCO, NCCN, and CDC all recommend routine vaccination for this population.